To compare intraocular pressure lowering effectiveness of a new fixed combination drug.

This is a multicentric, double blind and prospective clinical study. We will include patients with confirmed diagnosis of primary open-angle glaucoma and/or ocular hypertension, with intraocular pressure (IOP) ranging between 21 and 31 mm Hg. Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will receive 1 drop twice a day of either formulations and were examined at days 2, 7, 15, 30, 60, and 90 after initiation of treatment. The primary objective is to compare the efficacy of both formulations, estimated as a decrease in IOP. A Goldmann applanation tonometer will be used for IOP determination.

Inclusion Criteria:

• Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension;
• Visual acuity of 20/40 to 20/80 or better (Snellen equivalent).

Exclusion Criteria:

• Clinically relevant ophthalmic or systemic conditions may be excluded.

the evaluation of the adverse events was made during the 60 days of treatment and in a safety call at 15 days after the end of the clinical stage